Chronic Phase Chronic Myeloid Leukemia Patients With Low OCT-1 Activity Randomized to High-Dose Imatinib Achieve Better Responses and Have Lower Failure Rates Than Those Randomized to Standard-Dose Imatinib

Haematologica - Italy
doi 10.3324/haematol.2011.056457
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

Blood
BiochemistryImmunologyCell BiologyHematology
2003English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Clinical Journal of Oncology Nursing
Oncology
2009English

Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure

Haematologica
Hematology
2009English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Long-Term Molecular Responses to Imatinib in Patients With Chronic Myeloid Leukemia: Comparison Between Complete Cytogenetic Responders Treated in Early and in Late Chronic Phase

Haematologica
Hematology
2007English

Functional Activity of Cd34-Positive Cells in Chronic Myeloid Leukemia Patients With Different Response to Imatinib Therapy

Experimental Oncology
Cancer ResearchOncology
2015English

Polycomb Genes Are Associated With Response to Imatinib in Chronic Myeloid Leukemia

Epigenomics
Cancer ResearchGenetics
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy